InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the full record of transactions filed by Marks Gilbert Lynn. Director active across 1 company, notably AN2 Therapeutics, Inc.. Cumulatively, 3 disclosures have been published. History available since 19 December 2024. The latest transaction was disclosed on 10 October 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
3 of 3 declarations